Gennex Laboratories [GENNEX] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Gennex Laboratories
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gennex Laboratories wins in 6 metrics, Aarti Drugs wins in 13 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gennex Laboratories | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.87 | 23.77 | Gennex Laboratories |
| Price-to-Book Ratio | 1.14 | 3.28 | Gennex Laboratories |
| Debt-to-Equity Ratio | 13.93 | 44.92 | Gennex Laboratories |
| PEG Ratio | 0.81 | -21.01 | Aarti Drugs |
| EV/EBITDA | 11.60 | 17.16 | Gennex Laboratories |
| Profit Margin (TTM) | 11.69% | 7.80% | Gennex Laboratories |
| Operating Margin (TTM) | 3.65% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | 3.65% | 10.11% | Aarti Drugs |
| Return on Equity | 9.77% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 3.79% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $-197.44M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | -12.64% | -1.73% | Aarti Drugs |
| Price-to-Sales Ratio (TTM) | 2.18 | 1.85 | Aarti Drugs |
| Enterprise Value | $1.94B | $50.76B | Aarti Drugs |
| EV/Revenue Ratio | 1.41 | 2.10 | Gennex Laboratories |
| Gross Profit Margin (TTM) | 19.91% | 36.77% | Aarti Drugs |
| Revenue per Share (TTM) | $7 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $0.78 | $20.66 | Aarti Drugs |
| Beta (Stock Volatility) | 0.42 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Gennex Laboratories vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -0.65% | -2.30% | -3.91% | -2.15% | -11.06% | -28.24% |
| Aarti Drugs | -2.85% | 0.47% | 3.52% | 17.71% | 21.40% | 7.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -12.64% | 87.21% | 204.46% | 345.65% | 668.75% | 884.00% |
| Aarti Drugs | -1.73% | 18.09% | -4.28% | 213.79% | 2,742.22% | 2,387.47% |
Performance & Financial Health Analysis: Gennex Laboratories vs Aarti Drugs
| Metric | GENNEX | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.01B | ₹44.83B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 359,720 | 276,955 |
| 90 Day Avg. Volume | 540,131 | 692,287 |
| Last Close | ₹12.30 | ₹491.75 |
| 52 Week Range | ₹11.15 - ₹29.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -57.59% | -22.56% |
| All-Time High | ₹29.00 (Sep 16, 2024) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -57.59% | -52.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.20% | 0.06% |
| Quarterly Earnings Growth | -0.48% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.08% |
| Operating Margin (TTM) | 0.04% | 0.10% |
| Return on Equity (TTM) | 0.10% | 0.12% |
| Debt to Equity (MRQ) | 13.93 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹10.85 | ₹149.84 |
| Cash per Share (MRQ) | ₹3.23 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹-107,970,000 | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹-242,337,744 | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | ₹0.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Gennex Laboratories vs Aarti Drugs
| Metric | GENNEX | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.87 | 23.77 |
| Forward P/E | N/A | 15.13 |
| PEG Ratio | 0.81 | -21.01 |
| Price to Sales (TTM) | 2.18 | 1.85 |
| Price to Book (MRQ) | 1.14 | 3.28 |
| Market Capitalization | ||
| Market Capitalization | ₹3.01B | ₹44.83B |
| Enterprise Value | ₹1.94B | ₹50.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.41 | 2.10 |
| Enterprise to EBITDA | 11.60 | 17.16 |
| Risk & Other Metrics | ||
| Beta | 0.42 | 0.21 |
| Book Value per Share (MRQ) | ₹10.85 | ₹149.84 |
Financial Statements Comparison: Gennex Laboratories vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GENNEX | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹403.25M | ₹6.77B |
| Cost of Goods Sold | ₹322.95M | ₹4.37B |
| Gross Profit | ₹80.30M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-51.25M | ₹784.50M |
| EBITDA | ₹58.48M | ₹951.90M |
| Pre-Tax Income | ₹41.05M | ₹711.50M |
| Income Tax | ₹10.75M | ₹83.80M |
| Net Income (Profit) | ₹30.30M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GENNEX | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹5.53M | ₹45.80M |
| Total Current Assets | ₹1.81B | ₹13.38B |
| Total Current Liabilities | ₹445.53M | ₹8.37B |
| Long-Term Debt | ₹0 | ₹2.86B |
| Total Shareholders Equity | ₹1.95B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹566.08M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GENNEX | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENNEX | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 359,720 | 276,955 |
| Average Daily Volume (90 Day) | 540,131 | 692,287 |
| Shares Outstanding | 227.45M | 91.27M |
| Float Shares | 92.23M | 35.46M |
| % Held by Insiders | 0.31% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Gennex Laboratories vs Aarti Drugs
| Metric | GENNEX | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | ₹0.00 | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |